|
[1]
|
Wheeler, D.C., Stefánsson, B.V., Jongs, N., Chertow, G.M., Greene, T., Hou, F.F., et al. (2021) Effects of Dapagliflozin on Major Adverse Kidney and Cardiovascular Events in Patients with Diabetic and Non-Diabetic Chronic Kidney Dis-ease: A Prespecified Analysis from the DAPA-CKD Trial. The Lancet Diabetes & Endocrinology, 9, 22-31. [Google Scholar] [CrossRef]
|
|
[2]
|
Heerspink, H.J., Desai, M., Jardine, M., Balis, D., Meining-er, G. and Perkovic, V. (2017) Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. Journal of the American Society of Nephrology, 28, 368-375. [Google Scholar] [CrossRef]
|
|
[3]
|
李航. 肾脏在血糖调节中的作用[J]. 中国糖尿病杂志, 2016, 24(2): 184-186.
|
|
[4]
|
Ni, L., Yuan, C., Chen, G., Zhang, C. and Wu, X. (2020) SGLT2i: Beyond the Glucose-Lowering Effect. Cardiovascular Diabetology, 19, Article No. 98. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Kawanami, D., Matoba, K., Takeda, Y., Nagai, Y., Akamine, T., Yokota, T., et al. (2017) SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy. International Journal of Molecular Sciences, 18, Article No. 1083. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., et al. (2017) Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England Journal of Medicine, 377, 644-657. [Google Scholar] [CrossRef]
|
|
[7]
|
Terami, N., Ogawa, D., Tachibana, H., Hatanaka, T., Wada, J., Na-katsuka, A., et al. (2014) Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ame-liorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice. PLoS ONE, 9, Article ID: e100777. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Sanidas, E.A., Papadopoulos, D.P., Hatziagelaki, E., Grassos, C., Velliou, M. and Barbetseas, J. (2020) Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors across the Spectrum of Hypertension. American Journal of Hypertension, 33, 207-213. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Scheen, A.J. (2019) Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure. Current Cardiology Reports, 21, Article No. 70. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Vallon, V. and Thomson, S.C. (2017) Targeting Renal Glucose Reabsorption to Treat Hyperglycaemia: The Pleiotropic Effects of SGLT2 Inhibition. Diabeto-logia, 60, 215-225. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Castañeda, A.M., Dutra-Rufato, A., Juarez, M.J., Grosembacher, L., Gonzalez-Torres, H. and Musso, C.G. (2021) Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i): Renal Implications. International Urology and Nephrology, 53, 291-299. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Zhang, L., Zhao, M.H., Zuo, L., Wang, Y., Yu, F., Zhang, H., et al. (2020) China Kidney Disease Network (CK-NET) 2016 Annual Data Report. Kidney International Supplements, 10, e97-e185. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Wheeler, D.C., Stefansson, B.V., Batiushin, M., Bilchenko, O., Cherney, D.Z.I., Chertow, G.M., et al. (2020) The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) Trial: Baseline Characteristics. Nephrology, Dialysis, Transplantation, 35, 1700-1711. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Becker, M.A., Schumacher, H.R., Espinoza, L.R., Wells, A.F., MacDonald, P., Lloyd, E., et al. (2010) The Urate- Lowering Efficacy and Safety of Febuxostat in the Treatment of the Hyperuricemia of Gout: The CONFIRMS Trial. Arthritis Research & Therapy, 12, Article No. R63. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Mcgill, J.B. (2014) The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: A Bench to Bedside Review. Diabetes Therapy, 5, 43-63. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Ahmadieh, H. and Azar, S. (2017) Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus. Diabetes Technology & Therapeutics, 19, 507-512. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Andres-Hernando, A., Lanaspa, M.A., Kuwabara, M., Or-licky, D.J., Cicerchi, C., Bales, E., et al. (2019) Obesity Causes Renal Mitochondrial Dysfunction and Energy Imbalance and Accelerates Chronic Kidney Disease in Mice. American Journal of Physiology Renal Physiology, 317, F941-F948. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Tsimihodimos, V., Filippatos, T.D. and Elisaf, M.S. (2018) SGLT2 Inhibitors and the Kidney: Effects and Mechanisms. Diabetes & Metabolic Syndrome, 12, 1117-1123. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Consoli, A., Formoso, G., Baldassarre, M.P.A. and Febo, F. (2018) A Comparative Safety Review between GLP-1 Receptor Agonists and SGLT2 Inhibitors for Diabetes Treatment. Expert Opinion on Drug Safety, 17, 293-302. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Babitt, J.L. and Lin, H.Y. (2012) Mechanisms of Anemia in CKD. Journal of the American Society of Nephrology, 23, 1631-1634. [Google Scholar] [CrossRef]
|
|
[21]
|
Tsai, S.F. and Tarng, D.C. (2019) Anemia in Patients of Diabetic Kidney Disease. Journal of the Chinese Medical Association, 82, 752-755. [Google Scholar] [CrossRef]
|
|
[22]
|
Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheri-adou, I. and Tentolouris, N. (2019) SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. In-ternational Journal of Environmental Research and Public Health, 16, Article No. 2965. [Google Scholar] [CrossRef] [PubMed]
|